The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
© 2023. The Author(s)..
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory action. Fingolimod and siponimod have similar mechanisms of action, and consequently, their therapeutic effects may be comparable. However, while fingolimod is mainly used for relapsing-remitting MS (RRMS), siponimod, according to EMA label, is recommended for active secondary progressive MS (SPMS). Clinicians and scientists are analysing whether patients can switch from fingolimod to siponimod and identifying the advantages or disadvantages of such a switch from a therapeutic point of view. In this review, we aim to discuss the therapeutic effects of these two drugs and the advantages/disadvantages of switching treatment from fingolimod to siponimod in patients with the most common forms of MS, RRMS and SPMS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Drugs in R&D - 23(2023), 4 vom: 28. Dez., Seite 331-338 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vališ, Martin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fingolimod Hydrochloride |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 28.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40268-023-00434-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361388594 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361388594 | ||
| 003 | DE-627 | ||
| 005 | 20231226085031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40268-023-00434-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361388594 | ||
| 035 | |a (NLM)37640862 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vališ, Martin |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 28.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory action. Fingolimod and siponimod have similar mechanisms of action, and consequently, their therapeutic effects may be comparable. However, while fingolimod is mainly used for relapsing-remitting MS (RRMS), siponimod, according to EMA label, is recommended for active secondary progressive MS (SPMS). Clinicians and scientists are analysing whether patients can switch from fingolimod to siponimod and identifying the advantages or disadvantages of such a switch from a therapeutic point of view. In this review, we aim to discuss the therapeutic effects of these two drugs and the advantages/disadvantages of switching treatment from fingolimod to siponimod in patients with the most common forms of MS, RRMS and SPMS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
| 650 | 7 | |a G926EC510T |2 NLM | |
| 650 | 7 | |a siponimod |2 NLM | |
| 650 | 7 | |a RR6P8L282I |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Achiron, Anat |e verfasserin |4 aut | |
| 700 | 1 | |a Hartung, Hans Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Mareš, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Tichá, Veronika |e verfasserin |4 aut | |
| 700 | 1 | |a Štourač, Pavel |e verfasserin |4 aut | |
| 700 | 1 | |a Halusková, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Angelucci, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Pavelek, Zbyšek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs in R&D |d 1999 |g 23(2023), 4 vom: 28. Dez., Seite 331-338 |w (DE-627)NLM104905727 |x 1179-6901 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:4 |g day:28 |g month:12 |g pages:331-338 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40268-023-00434-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 4 |b 28 |c 12 |h 331-338 | ||